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Carbon monoxide releasing molecules (CORMs) have been suggested as a new
synthetic class of antimicrobials to treat bacterial infections. Here we utilized a novel
EBOR-CORM-1 ([NEt4][MnBr2(CO)4]) capable of water-triggered CO-release, and tested
its efficacy against a collection of clinical Pseudomonas aeruginosa strains that differ
in infection-related virulence traits. We found that while EBOR-CORM-1 was effective
in clearing planktonic and biofilm cells of P. aeruginosa strain PAO1 in a concentration
dependent manner, this effect was less clear and varied considerably between different
P. aeruginosa cystic fibrosis (CF) lung isolates. While a reduction in cell growth was
observed after 8 h of CORM application, either no effect or even a slight increase in
cell densities and the amount of biofilm was observed after 24 h. This variation could
be partly explained by differences in bacterial virulence traits: while CF isolates showed
attenuated in vivo virulence and growth compared to strain PAO1, they formed much
more biofilm, which could have potentially protected them from the CORM. Even though
no clear therapeutic benefits against a subset of isolates was observed in an in vivo wax
moth acute infection model, EBOR-CORM-1 was more efficient at reducing the growth
of CF isolate co-culture populations harboring intraspecific variation, in comparison with
efficacy against more uniform single isolate culture populations. Together these results
suggest that CORMs could be effective at controlling genetically diverse P. aeruginosa
populations typical for natural chronic CF infections and that the potential benefits of
some antibiotics might not be observed if tested only against clonal bacterial populations.
Keywords: biofilms, carbon monoxide releasing molecules, CORM, cystic fibrosis, polymicrobial infections,
Pseudomonas aeruginosa, synthetic chemistry, virulence
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INTRODUCTION
The rapid emergence of multidrug-resistant bacteria is a global
problem that is predicted to cause 10 million deaths per year
by 2050 (O’Neill, 2014). Antibiotic resistance often evolves very
quickly via de novo mutations and horizontal gene transfer
(Normark and Normark, 2002), and as a result, antibiotic
discovery has not been able to replace all of the antibiotics that
have now become ineffective (Brown and Wright, 2016). New
methods and approaches for treating bacterial infections are thus
urgently required.
In recent years, carbon monoxide has emerged as a new
potential therapeutic due to its properties as a homeostatic and
cytoprotective molecule with important signaling capabilities
(Motterlini and Otterbein, 2010). Carbon monoxide can be
delivered via carbon monoxide releasing molecules (CORMs),
which are small molecules that release carbon monoxide in
response to certain environmental triggers such as enzymes
(Stamellou et al., 2014) or light (Jimenez et al., 2016). Nobre
et al. first investigated the effect of CORMs on bacteria (Nobre
et al., 2007) and found that CORM-2 and CORM-3 reduced the
number of colony-forming units of Escherichia coli in minimal
salts media and Staphylococcus aureus in Luria Broth (LB) media
(Nobre et al., 2007). The CORM effects were stronger in near-
anaerobic conditions and the activation of CORM required
direct contact between the molecule and its cellular targets
(Nobre et al., 2007). Moreover, the effect of CORM-3 on
Pseudomonas aeruginosa wild type strain PAO1 was investigated
by Desmard et al. (2009), who found that treatment with the
CORM reduced bacterial densities and increased the survival
of immunocompromised mice during an infection. It has also
previously been found that CORM-2 effectively reduces the
densities of P. aeruginosa planktonic and biofilm cultures with
wild type and clinical strains (Murray et al., 2012). Another
study found that manganese-based Trypto-CORM is able to
inhibit the growth of E. coli when exposed to photochemical
stimulus (Ward et al., 2014), while in the dark it is active against
Neisseria gonorrhoeae (Ward et al., 2017). In both cases, control
experiments indicate that the CO liberated from the metal is
responsible for the observed behavior. However, most of the
studies thus far have concentrated on exploring CORM effects on
relatively short time span (<24 h). Furthermore, although it has
been established that many infections are polymicrobial, and that
clinical bacterial pathogens can respond differently to CORMs
than laboratory strains, no studies have explored CORM effects
on bacterial co-cultures.
Cystic fibrosis (CF) is a genetically inherited disease which
affects 1 in 2,000 to 3,000 newborn infants in the EU (Who.Int,
2010). Patients with CF often develop a thick mucus in the lungs
which they are unable to clear (Flume et al., 2010). This mucus
makes patients susceptible to frequent and recurring bacterial
chest infections and the presence of P. aeruginosa is often
associated with increasing morbidity and loss of lung function
(Pritt et al., 2007). One of the key features of P. aeruginosa is
its capability to rapidly adapt to the lung environment and to
become highly resistant to the antibiotics that are used to treat
infections (Smith et al., 2006; Poole, 2011; Folkesson et al., 2012;
Winstanley et al., 2016). As a result, P. aeruginosa populations
show high levels of genetic variation within and between CF
patients (Marvig et al., 2013; Williams et al., 2015; O’Brien
et al., 2017). This includes phenotypic and genomic heterogeneity
within genetically-related populations of P. aeruginosa derived
from the same clonal lineage (Mowat et al., 2011; Workentine
et al., 2013; Williams et al., 2015). This variation might also affect
the applicability of potential alternative therapies if it is linked
with bacterial life-history traits that relate to potential resistance
mechanisms.
Here we synthesized and characterized a water-soluble
CORM (EBOR-CORM-1), [NEt4][MnBr2(CO)4], and tested its
effectiveness against P. aeruginosa strain PAO1 and a selection
of P. aeruginosa CF isolates originating from a single sputum
sample from the lungs of a CF patient, namely patient CF03
from previously published studies (Mowat et al., 2011; Williams
et al., 2015). Based on genome sequence data presented in
a previous study, these CF isolates were classified into two
genetically distinct Liverpool Epidemic Strain (LES) lineages, A
and B (Williams et al., 2015, 2016), that differ regarding their
virulence traits (O’Brien et al., 2017). These genetically diverged
lineages have been shown to commonly coexist within individual
patients and to share mutations via homologous recombination
that potentially help strains to adapt to the airway during chronic
infection (Williams et al., 2015). However, the implications of
within-patient genetic variation have been seldom considered
in the context of antimicrobial therapies. We hypothesized that
effects of EBOR-CORM-1 could vary between different clinical
isolates and lineages, and that the susceptibility of isolates
could be linked to expression of some other bacterial virulence
factors. We found that the CORM was effective in reducing
both planktonic and biofilm cells of strain PAO1 in a density-
dependent manner. However, CORM effects were more varied
and generally weaker against clinical CF isolates. Regardless,
CORM efficiently reduced the growth of CF strain lineage
co-cultures, which suggest that CORMs could be effective at
controlling genetically diverse P. aeruginosa infections.
MATERIALS AND METHODS
Synthesis and Properties of
[NEt4][MnBr2(CO)4], EBOR-CORM-1
EBOR-CORM-1 was synthesized as described previously
(Angelici, 1964): Mn(CO)5Br (466mg, 1.69 mmol) and 330mg
(1.57 mmol) of [(C2H6)4N]Br were heated in 18mL of absolute
methanol under a nitrogen atmosphere at 50◦C for 1 h. The
methanol was then evaporated from the orange solution at the
above temperature. The remaining yellow solid was dissolved
in 40mL of chloroform, and the solution was filtered under
nitrogen. After adding 200mL of hexane to the filtrate, the
cloudy solution was allowed to stand under nitrogen for 2 h. The
air-stable yellow crystals were separated by filtration, washed
with hexane, and dried under vacuum giving a yield of 88%
(636mg). The compound was characterized via solid state IR
spectroscopy recorded using a KBr disk. Four main bands were
seen at 2,090, 2,001, 1,984, and 1,942 cm−1 and a small shoulder
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was seen at 1,897 cm−1. This is consistent with the literature
values (Angelici, 1964). In a chloroform solution of CORM four
distinct bands were observed at 2,092, 2,015, 1,987, and 1,943
cm−1, again this is similar to previously reported literature values
(Angelici, 1964). The change in the number of carbonyl bands
between the solid and solution phase measurements typically
reflects that different orientations are present in the solid state.
The stability of the CORM in the solid state was tested by heating
a sample to 50◦C and running ATR IR spectra at 1 h intervals.
Infrared detection of CO release from EBOR-CORM-1
following dissolution in different solvents was conducted by
dissolving 12mg of CORM in 4mL of solvent in a 25mL round-
bottomed flask attached to a vacuum evacuated gas IR cell via
a closed tap. After 1 h of stirring the flask, the tap was opened
to enable gas from the headspace of the flask to enter the IR
cell. Carbonmonoxide could then be identified via the distinctive
gaseous IR signature of a double band, with fine rotational
splitting, centered at 2,150 cm−1 (Klein et al., 2014). The impact
of different solvents can be quantified by comparison of the
intensity of the CO bands to those from CO2, which is assumed
to act as an effective internal standard.
The release of CO from EBOR-CORM-1 following dissolution
in water was also followed via solution phase monitoring of
the metal complex’s IR bands. In contrast to chloroform, when
EBOR-CORM-1 was first dissolved in water only two main IR
bands were observed at 2,050 and 1,943 cm−1. In order to
investigate activity of EBOR-CORM-1 in liquid culture media,
we compared the effects of active and “inactivated” CORM on
the growth of PAO1 strain in LB media as described previously
(Murray et al., 2012). Briefly, CORM was inactivated by storing
a 2mM CORM stock LB solution (10% v/v of standard LB
concentration, i.e., the same that was used in all the experiments;
see below) at room temperature for 24 h. To estimate the
effect of CORM inactivation on PAO1 growth, we added 50µL
of freshly prepared 2mM CORM, 50µL of inactivated 2mM
CORM or 50µL 10% v/v LB (control) to 150µL of PAO1 starter
culture on 96-well microplate. All treatments were replicated
five times and PAO1 growth monitored for 8 h at 37◦C with a
spectrophotometer (OD 600 nm; Tecan Infinite).
Bacterial Strains and Culture Media
In this study we used P. aeruginosa strain PAO1 (ATCC 15692),
the earliest archived isolate of the Liverpool Epidemic strain,
LESB58 (Winstanley et al., 2009), and 19 clinical P. aeruginosa
LES isolates from the same sputum sample of a chronically
infected CF patient (Williams et al., 2015). The CF lung LES
isolates originate from the sputum sample of one patient,
identified as patient CF03 in previous studies, and consist of
two genetically separate lineages A and B (Williams et al., 2015).
Lineage A was represented by six isolates, namely isolates: 2, 5,
10, 19, 23, and 25. Lineage B was represented by 13 isolates,
namely isolates: 1, 6, 8, 17, 24, 26, 28, 32, 33, 34, 35, 36,
and 37. Clinical isolates were collected with the consent of the
patient and under institutional human investigation approval.
All strains and isolates of P. aeruginosa were routinely cultured
in liquid or solid LB media containing 10.0 g tryptone, 5.0 g
yeast extract and 10.0 g NaCl in 1 L of ultra-pure water (final pH
adjusted to 7.0 and 15 g of agar was used for solid media). For
all experiments, starter cultures were prepared from cryofrozen
stocks by streaking frozen stock culture onto LB plates. After 24 h
growth, a single colony was selected and inoculated into 5mL of
liquid LB and grown overnight in a shaking incubator at 37◦C
in 50mL centrifuge tubes. Overnight cultures were centrifuged at
4,000 rpm (11.5 g) for 15min (Eppendorf), the resultant pellets
were suspended in 10% LB and bacterial densities adjusted to
optical density at 600 nm of 0.066 before use (OD 600 nm),
equalling approximately 1× 108 cells mL−1.
Measuring the Effects of EBOR-CORM-1
Concentration on P. aeruginosa PAO1
Strain
Wemeasured the effect of CORM concentration on P. aeruginosa
PAO1 in four different ways. First, we examined how EBOR-
CORM-1 affects PAO1 growth after both 8 and 24 h of
inoculation in 10% LB media (bacteria and CORM inoculated
at the same time). Additionally, we measured how effective
EBOR-CORM-1 is at clearing both established planktonic
and biofilm PAO1 cultures (bacteria pre-grown before adding
EBOR-CORM-1). All measurements were conducted on 96-well
microplates and each treatment was replicated 5 times. A variety
of EBOR-CORM-1 concentrations were tested by first preparing
a 4mM CORM stock solution (dissolving EBOR-CORM-1 in
10% LB media by vortexing for 30 s and sonicating for 1.5min).
The stock solution was then sterilized with syringe filtration and
serially diluted to result in 1, 0.5, 0.25, 0.125, and 0mM (control)
EBOR-CORM-1 concentrations and 1 × 108 PAO1 cells mL−1
with final volume of 200µL of media. The microplate was then
incubated at 37◦C for 24 h.
All replicate populations were sampled at 8 and 24 h after the
start of the experiment (20µL of samples) and serially diluted in
sterile PBS on microplates to quantify the number of living vs.
dead cells by flow cytometry. Briefly, DAPI (4′,6-diamidino-2-
phenylindole for dead and living cells) and PI (Propidium iodide
for dead cells) fluorescent stains (both from Sigma-Aldrich)
were added to microplate wells with diluted bacterial samples at
concentrations of 1µg/mL and 50µM, respectively. Plates were
then incubated at room temperature for 1 h before measuring
cell densities with a Cytoflex flow cytometer and the CytExpert
program. Every well was sampled for 60 s at fast speed setting.
Gating of live and dead cells was performed by monitoring DAPI
staining on the PB450 channel with the 405 nm laser, and PI
staining on the ECD channel of the 488 nm laser. Number of
living cells was determined as total cells (DAPI)–dead cells (PI).
To quantify the effects of EBOR-CORM-1 on established
planktonic and biofilm cultures, PAO1 was first grown in the
absence of CORM at 37◦C for 48 h. Cell cultures were then
inoculated with stock CORM solution to reach the same final
concentrations as above: 1, 0.5, 0.25, 0.125, and 0mM (control)
of CORM. The plate was incubated for four more hours at
37◦C before sampling (20µL), serial dilution and flow cytometry
as described above. To quantify effects of EBOR-CORM-1 on
biofilm, crystal violet was added to the remaining cell cultures
at 10% v/v. After 15min of incubation, the plate was rinsed with
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deionised water and solubilised with 228µL ethanol per well. The
biofilm was quantified by measuring absorbance at 600 nm.
Measuring the Effects of EBOR-CORM-1
on Clinical P. aeruginosa Isolates in Mono-
and Co-cultures
Similar to the PAO1 strain experiments, we measured the effect
of EBOR-CORM-1 on clinical P. aeruginosa isolates after 8 and
24 h of inoculation in 10% LB media. We also measured the
impact of growing the isolates in the absence of EBOR-CORM-
1 for 48 h and then applying EBOR-CORM-1 for 4 h using
both flow cytometry and crystal violet staining. We used only
one EBOR-CORM-1 concentration, 0.5mM, which resulted in
clear reduction of PAO1 cultures (see Results) alongside control
treatment (no CORM).
In addition to measuring the effects of EBOR-CORM-1 in
monocultures of each clinical isolate, we also quantified the effect
of the CORM on mixtures of the CF clinical isolates from patient
CF03. First, we prepared the clinical isolate starter cultures as
described above, then we mixed the standardized monocultures
together in three different ways: as a whole mix (all isolates
mixed together in equal proportions), lineage A mix (all isolates
classified as lineage A mixed together in equal proportions) and
lineage B mix (all isolates classified as lineage B mixed together
in equal proportions). All final mixes contained approximately
1 × 108 cells mL−1 before the application of 0.5mM of EBOR-
CORM-1. Each experiment was replicated 5 times. After 24 h
growth at 37◦C, bacterial densities were measured by using a
Tecan infinite spectrophotometer: optical density measurements
correlate well with the proportion of living cells measured by flow
cytometry (Supplementary Figure 1).
Characterizing Bacterial Virulence and
Growth
To characterize production of the virulence factors pyocyanin
and pyoverdine, all clinical isolates were grown in 200µL of
10% LB media in round-bottomed 96-well microplates for 48 h
at 37◦C (no shaking). After incubation, wemeasured the bacterial
densities (OD 600 nm) and centrifuged themicroplate for 10min.
at 4,000 rpm (11.5 g) in a swing rotor Eppendorf centrifuge.
To measure pyocyanin and pyoverdine production, 150µL of
the supernatant of each well was transferred to flat-bottomed
96-well microplates and the absorbance spectrum measured
with a spectrophotometer (Tecan infinite). Per capita pyocyanin
production was measured for each isolate by measuring the
absorbance of supernatant at 691 nm, and then standardizing
by bacterial OD (Reszka et al., 2004). Per capita production of
the iron-chelating siderophore, pyoverdine, was measured by
using excitation-emission assay (O’Brien et al., 2017) where the
fluorescence of each supernatant well was measured at 470 nm
following excitation at 380 nm, using a Tecan infinite M200
pro spectrophotometer. Also, OD was measured at 600 nm to
quantify the ratio fluorescence/OD as a quantitative measure
of per capita pyoverdine production (O’Brien et al., 2017). The
isolate biofilm production was measured as described previously
and growth as maximum density and growth rate h−1 during
24-h growth period. Lastly, we also measured the in vivo
virulence of each isolate by using wax moth model as described
previously (O’Brien et al., 2017).
Testing EBOR-CORM-1 Antimicrobial
Activity in Wax Moth Model In vivo
To test the efficacy of EBOR-CORM-1 to constrain bacterial
infections in vivo, we used a wax moth larvae model
(Galleria mellonella [Lepidoptera: Pyralidae], Livefood UK Ltd.)
and followed the infection methodology described previously
(O’Brien et al., 2017). We chose three strains for infection
experiments: PAO1, LESB58 and isolate 36 (Lineage B) from
the clinical sample collection. Before infection, we first grew the
selected P. aeruginosa isolates for 24 h at 37◦C and subsequently
diluted all cultures to approximately similar densities (equalling
approximately 1 × 106 cells mL−1 in 0.8% w:v NaCl). The
virulence of every isolate was then tested in 16 independent wax
moth larvae. We also infected 16 larvae with 0.8% w/v NaCl
salt solution to control for the damage caused by the injection
itself. The larvae were injected with either 20µL of one bacterial
solution or NaCl buffer (“non-infected”) between the abdominal
segments six and seven with a 1mL Terumo syringe. After 2 h, 8
larvae from each bacterial infection or non-infection group were
treated with 20µL injection of 500µM EBOR-CORM-1, and the
other 8 were injected with 0.8% w:v NaCl salt solution (control
placebo) in the same location where the bacteria were originally
injected. After infection, larvae were placed on individual wells of
24-well cell culture plates and the survival was monitored at 2-h
intervals for 3 days at 37◦C. Larvae were scored as dead when
they did not respond to touch with forceps. Larvae that were
still alive after 7 days from the infection were given a time of
death of 168 h. Every bacterial isolate was tested for three times.
It was concluded that the EBOR-CORM-1 injection alone did not
affect larval survival in the absence of bacteria (mortality similar
between non-infected CORM-injected larvae and non-infected
CORM-free larvae: 5–10%).
Statistical Analysis
All data were analyzed with Generalized Mixed Models (factorial
ANOVA) or regression analysis where bacterial densities
(Figures 2, 3, and 4B) or trait values (Figure 4A; Supplementary
Figure 4) were explained with the presence and/or concentration
of EBOR-CORM-1, CF isolate identity (isolate number) or
CF lineage (A or B). All proportional data (%) were arcsine
transformed before the analysis to meet the assumptions of
parametric models.
RESULTS
Chemistry of EBOR-CORM-1
The stability of EBOR-CORM-1 in the solid state was
demonstrated by heating a sample of solid to 50◦C in air, and
showing that there is very little difference in the carbonyl bands
observed in ATR IR spectra measured at 1 h intervals over a
3-h period (Figure 1A). In contrast, gas phase infrared analysis
proved that CO release from EBOR-CORM-1 can be triggered by
dissolution in water, phosphate buffer or LB media, or addition
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of water to a solution of the compound in an organic solvent
(Figure 1B).
Solution phase monitoring of the CO stretches of the
compound showed that there was no reaction with water
over short periods of time, since dissolving EBOR-CORM-1
in water, immediately re-drying it on a vacuum line and then
re-dissolving the resultant solid in chloroform yielded an IR
spectrum which matched that of the as-purified compound in
chloroform (Figure 1C). The only two observed IR bands in the
CORM spectrum in water (2,050 and 1,943 cm−1) were therefore
attributed to the molecular symmetry of the hydrated complex,
rather than an immediate loss of CO upon contact with water.
However, after 90min in water, a loss of these carbonyl bands
was observed, and this was attributed to the release of all the CO
from the complex (Figure 1D).
EBOR-CORM-1 Activity against Planktonic
and Biofilm Cells of P. aeruginosa PAO1
We found that applying EBOR-CORM-1 had generally negative
effects on P. aeruginosa PAO1 growth both after 8 and 24 h
of application [F(4, 25) = 50.9, p < 0.001 and F(4, 25) = 31.8,
p < 0.001 for proportion of living cells after 8 and 24 h,
respectively, Figure 2A] and that these negative effects increased
along with the increasing concentration of applied EBOR-
CORM-1 [regression analysis: F(1, 24) = 43, p < 0.001 and
F(1, 24) = 35, p < 0.001 for proportion of living cells after
8 and 24 h, respectively, Figure 2A]. Similarly, EBOR-CORM-
1 was highly effective against both established planktonic and
biofilm P. aeruginosa PAO1 cultures [F(4, 25) = 77.5, p < 0.001
and F(4, 25) = 39.5, p < 0.001, respectively, Figures 2A,B] and
the antimicrobial activity of the CORM increased in a density-
dependent manner [regression analysis: F(1, 24) = 92, p < 0.001
and F(1, 24) = 54, p < 0.001, respectively, Figures 2A,B].
EBOR-CORM-1 Activity against Planktonic
and Biofilm Cells of Clinical P. aeruginosa
Cystic Fibrosis Isolates
Similar to strain PAO1, we found that EBOR-CORM-1 had
inhibitory effects on all tested clinical P. aeruginosa isolates after
8 h of application of CORM [F(1, 152) = 11,969, p < 0.001,
Figure 3A]. While this effect did not depend on the lineage
FIGURE 1 | The stability of EBOR-CORM-1. (A) shows the IR spectra of EBOR-CORM-1 upon heating at 50◦C for 0 h (black line), for 1 h (red line), for 2 h (blue), and
for 3 h (pink). The structure of the EBOR-CORM-1 is shown in inset on the left. (B) shows the gas phase IR spectra obtained from EBOR-CORM-1 in chloroform with
added water where the * indicates a band from chloroform. (C) shows the IR spectra of EBOR-CORM-1 in chloroform (top) and water (bottom) and (D) the IR spectra
of CO in water after 1min (top) and 90min (bottom) dissolution. All wavenumbers are given in cm−1.
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[CORM × lineage: F(1, 152) = 1.4, p < 0.001], it varied between
different clinical isolates [CORM × isolate: F(18, 152) = 11,969,
p < 0.001, Figure 3A]. In contrast, EBOR-CORM-1 had slightly
positive effects on P. aeruginosa growth after 24 h of application
[F(1, 152) = 256, p < 0.001, Figure 3B] and this effect varied
between different isolates [CORM × strain: F(18, 152) = 2.8,
FIGURE 2 | The EBOR-CORM-1 effects on planktonic and biofilm cells of P. aeruginosa PAO1. In (A), different lines denote for cell densities after 8 h (blue line) and
24 h (green line) of EBOR-CORM-1 application and EBOR-CORM-1 effects on established cell cultures (red line) in different CORM concentrations. (B) shows
EBOR-CORM-1 effects on PAO1 biofilms in different CORM concentrations. The R2 denotes for the fit of regression with our data, and in (B), bars denote for ±1 s.e.m.
FIGURE 3 | The EBOR-CORM-1 effects on planktonic and biofilm cells of clinical P. aeruginosa CF isolates. (A,B) show the proportion of living cells after 8 and 24 h of
EBOR-CORM-1 application, respectively. (C,D) show the EBOR-CORM-1 effects on established cell cultures and biofilms, respectively. In all panels, bars denote
for ±1 s.e.m.
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p = 0.001] being slightly stronger (i.e., positive) with isolates
belonging to a lineage B [CORM × lineage: F(1, 152) = 24.9,
p < 0.001, Figure 3B]. EBOR-CORM-1 also had negative
effects when applied to established P. aeruginosa cell cultures
[F(1, 152) = 222, p < 0.001, Figure 3C]. However, these effects
depended on the isolate [CORM × isolate: F(18, 152) = 2.8,
p= 0.001] and the lineage [F(1, 152) = 65.2, p= 0.001], reduction
being relatively larger with isolates belonging to lineage A
(Figure 3C). In the case of established biofilms, EBOR-CORM-
1 had a slightly positive effect [F(1, 152) = 9.6, p = 0.002,
Figure 3D] and while this effect varied between different isolates
[F(18, 152) = 2.0, p = 0.01] it did not differ between the lineages
[F(1, 152) = 1.2, p = 0.265, respectively, Figure 3D]. Together
these results suggest that compared to strain PAO1, EBOR-
CORM-1 effects varied more with the clinical P. aeruginosa
isolates having negative, neutral or positive effects on bacterial
growth depending on the isolate identity, lineage and the timing
of CORM application.
Linking EBOR-CORM-1 Antimicrobial
Activity with Clinical P. aeruginosa Isolate
Virulence and Growth
We found that all the isolates belonging to a lineage A formed
non-mucoid colonies (6 out of 6), while most of the isolates
belonging to a lineage B formed mucoid (i.e., mucus-like)
colonies (11 out of 13) on LB plates (typical mucoid and
non-mucoid colonies shown in Supplementary Figure 3). All
clinical isolates differed from the non-mucoid PAO1 strain
respective of their virulence and growth (Figure 4A). More
specifically, clinical isolates produced less pyoverdine [F(1, 23) =
286, p < 0.001] and pyocyanin [F(1, 23) = 170, p < 0.001] and
grew slower [F(1, 23) = 91, p< 0.00] and reached lower maximum
densities in LB medium [F(1, 23) = 15.5, p = 0.001, Figure 4A].
However, clinical isolates produced a considerably larger amount
of biofilm [F(1, 23) = 21.7, p < 0.001] and showed very low
virulence (high time to death) in wax moth larvae in vivo [F(1, 23)
= 1296, p < 0.001, Figure 4A].
When comparing the two CF lineages, we found that isolates
belonging to a lineage B consistently outperformed the isolates
belonging to a lineage A by producing more pyoverdine [F(1, 18)
= 6.06, p = 0.025], biofilm [F(1, 18) = 15.08, p = 0.001] and
by growing faster [F(1, 18) = 22.35, p < 0.001] and to higher
maximum densities [F(1, 18) = 6.27, p = 0.023] in LB medium
(Figure 4A; Supplementary Figure 4). However, lineages did not
differ in pyocyanin production [F(1, 18) = 1.99, p = 0.176] or
virulence [F(1, 18) = 1.03, p = 0.324; Figure 4A; Supplementary
Figure 4]. Across all clinical isolates, density reduction by CORM
correlated negatively with biofilm formation [F(1, 18) = 4.8,
p = 0.042]. Together these results suggest that clinical isolates
differed from PAO1 and from each other respective to various
life-history traits important for establishing an infection.
EBOR-CORM-1 Activity against Clinical
P. aeruginosa CF Isolate Co-cultures
Despite the observed isolate-specific variation in P. aeruginosa
monocultures, EBOR-CORM-1 was effective in reducing the
growth of P. aeruginosa co-cultures after 24 h of application
[CORM: F(1, 24) = 132, p < 0.001, Figure 4B]. Moreover, this
reduction was the same regardless of whether the mix contained
only one lineage or both lineages [CORM × co-culture: F(2, 24)
= 0.5, p = 0.612]. These results suggest that intraspecific
P. aeruginosa population heterogeneity makes the bacteria more
susceptible to EBOR-CORM-1 treatment.
EBOR-CORM-1 Activity against
P. aeruginosa Strains in Wax Moth Model
We found that P. aeruginosa isolates differed in their virulence
(time to death) from each other [F(2, 24) = 12.2, p < 0.001]:
PAO1 and LESB58 strains were equally virulent, and both
FIGURE 4 | Differences in P. aeruginosa growth and virulence trait variation between PAO1 and clinical CF isolates (A) and EBOR-CORM-1 effects on clinical CF
isolate lineage mixes (B). In (A), different colors denote for pyocyanin (blue) and pyoverdine (green) production, time to death (black), growth rate (purple), maximum
density (yellow) and biofilm production for clinical isolates belonging to lineages (A,B). The dashed line shows the mean performance of PAO1 strain. (B) shows
EBOR-CORM-1 effect on clinical CF isolate mixes after 24 h of CORM application. In (A), bars denote for ±1 s.e.m., and in (B), extreme values around lower and
upper quartile (black lines show the median).
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exhibited higher virulence than the clinical isolate 36 (killing
larvae approximately in 17 h [PAO1], 36 h [LESB58], and 92 h
[clinical isolate 36]; values averaged over both non-CORM and
CORM treatments, Figure 5). In contrast to in vitro results,
application of EBOR-CORM-1 did not increase the survival of
infected larvae [F(1, 24) = 1.3, p= 0.257] with any of the infected
strains [CORM × strain: F(2, 24) = 1.4, p = 0.273, Figure 5]. All
larvae became highly pigmented (black throughout) during the
infection regardless of the P. aeruginosa isolate.
DISCUSSION
Here we set out to study the antimicrobial activity of
[NEt4][MnBr2(CO)4], EBOR-CORM-1, against clinical
P. aeruginosa isolates in vitro. This CORM was chosen as a
suitable representative of this class of molecule based on the
aqueous solubility, facile synthesis (Angelici, 1964), content of
a non-toxic metal core, and simple architecture which makes
it akin to a “parent compound” for CORMs that have been
engineered to possess sophisticated CO release mechanisms. In
contrast to more complex CORMs, the molecule was shown
to have a water activated mechanism of CO release, as seen in
previous studies of [MX(CO)5]
− species, where X is a halide
(Zhang et al., 2009). Such water induced degradations are
believed to proceed via a two-step pathway whereby water causes
loss of the halide followed by formation of a dimer species; from
which the CO is released. This may explain the changes in the
IR spectra recorded in water when compared to chloroform,
although the data do not directly match those for [Mn2Br2(CO)8]
(El-Sayed and Kaesz, 1963), the product expected on loss of Br−
from EBOR-CORM-1. We found that while EBOR-CORM-1
showed density-dependent antimicrobial activity against both
FIGURE 5 | The EBOR-CORM-1 activity against three P. aeruginosa strains in
wax moth model. Boxplots show larval survival in the absence (light gray) and
presence (blue) of EBOR-CORM-1 for PAO1, LESB58 and clinical isolate #36
(lineage B). Bars show extreme values around lower and upper quartile and
black lines show the median.
planktonic and biofilm cells of the widely studied laboratory-
adapted strain PAO1, these effects were more varied and weaker
against clinical CF lung isolates. Regardless, EBOR-CORM-1 was
efficient at reducing the growth of CF isolate lineagemixes, which
suggests that it could have therapeutic potential in controlling
heterogeneous P. aeruginosa infections. Solutions of inactivated
EBOR-CORM-1 were essentially inactive against P. aeruginosa
strain PAO1 (Supplementary Figure 2) implying that, at least in
this case, the observed activity was due to CO released from the
complex rather than the residual metal salts (or indeed [NEt4]
+).
Similar to a study published by Murray et al. (2012), we
found considerable variation in CORM antimicrobial activity
between different clinical CF isolates, which depended whether
we explored EBOR-CORM-1 effects on relatively short (8 h) or
long timescales (24 h) and if we compared CORM antimicrobial
activity on actively growing and established cell cultures (after
48 h of bacterial growth). Our results after 8 h of EBOR-CORM-1
application are very similar to a previous study (Murray et al.,
2012) showing clear reduction in bacterial densities. However,
this effect vanished by the 24 h time point, and surprisingly,
some bacterial isolate cultures reached higher optical densities
in the presence compared to absence of CORM, which could
have been due to increase in number of cells or expression of
exoproducts that were picked up by OD600 nm (e.g., pyocyanin
or alginate). The most likely explanation for this is that CORM
effects were short-lived (Figure 1), which allowed bacteria to
recover and grow to high densities during 24 h after application
of CORM. However, when CORM effects were measured after
4 h of application to established cell cultures, we could still
observe clear reduction in mean bacterial densities. Together
these results suggest that CORM effects could be seen up to
4 h post application and that CORM could eradicate bacterial
cells whether they are at exponential or stationary phase of
their growth. Interestingly, CORM effects varied between clinical
isolates and were clearer with the isolates belonging to lineage
A. While Murray et al. (2012) did not observe clear variation
in CORM effects against planktonic cell cultures, they found
differences in CORM efficiency in eradicating bacterial biofilms.
This is also consistent with our data and reinforces the hypothesis
that P. aeruginosa clinical isolates are likely to respond differently
to CORM therapies.
To explore clinical isolate variation in more detail, we
compared differences in bacterial virulence and growth traits
between the PAO1 and clinical CF lung isolates. We found that
relative to strain PAO1, clinical CF isolates grew slower, had
lowered virulence and produced lower amounts of pyoverdine
and pyocyanin, which are important virulence factors (O’Brien
et al., 2017). This is consistent with previous research and typical
for P. aeruginosa isolates retrieved from chronic lung infections
(Smith et al., 2006; Folkesson et al., 2012; Marvig et al., 2013;
Williams et al., 2015). The clinical isolates produced much
more biofilm compared to strain PAO1 and biofilm formation
was the highest in the isolates belonging to lineage B. Biofilms
could potentially provide a protective function against CORMs.
Biofilms often have much higher antibiotic resistance than their
aquatic counterparts (Stewart and William Costerton, 2001) and
there are multiple reasons for this. First, antibiotics might be
Frontiers in Microbiology | www.frontiersin.org 8 February 2018 | Volume 9 | Article 195
Flanagan et al. CORM Activity on Pseudomonas aeruginosa
ineffective because the biofilm acts as a diffusion barrier (de
Beer et al., 1997). Second, subpopulations within the biofilm can
sometimes differentiate into a highly protected phenotypes that
can repopulate the biofilms (Cochran et al., 2000). Third, the
biofilm might change the chemical microenvironment, forming
zones of nutrient and oxygen depletion or waste accumulation
that prevents the antibiotics from functioning optimally (de
Beer et al., 1994). Although we did not explore this specifically,
clinical isolates belonging to a lineage A were more susceptible to
CORMs and produced relatively less biofilm compared to strains
belonging to a lineage B. Thus, overall a negative correlation
was found between density reduction by CORM and biofilm
formation. Our results therefore suggest that biofilm might
provide a protective function against the CORM.
Despite the isolate variations observed in bacterial
monocultures, EBOR-CORM-1 was effective at reducing
the growth of P. aeruginosa clinical isolate mixed cultures. One
explanation for this is that, in addition to CORM, P. aeruginosa
growth was limited by antagonistic intraspecific species
interactions in co-cultures. P. aeruginosa has been shown to
exert both facilitative and antagonistic effects on each other
via siderophore (Harrison et al., 2008) and bacteriocin (Ghoul
et al., 2015) production. In our case, all the clinical isolates were
derived from the same Liverpool Epidemic Strain clonal lineage
and therefore likely carried the same siderophore and bacteriocin
genes. Additionally, resource competition is likely to further limit
P. aeruginosa growth both in CF lungs and simplified laboratory
microcosms. As a result, even though some clinical strains were
relatively insensitive to EBOR-CORM-1, their growth could
have been constrained by competition with the other strains in
co-cultures. We found that this was the case for all strain mixes
regardless if the strains belonged to a lineage A, B or them both.
This suggests that the susceptibility of the lineages measured in
monocultures did not predict the susceptibility of isolate mixes
within or between lineages. However, such antagonism was not
observed in the absence of EBOR-CORM-1, which suggests
that CORM-triggered antagonistic intraspecific interactions
in P. aeruginosa co-cultures. Mechanistically, this could have
been driven by competition sensing in response to CORM-
mediated cell damage in P. aeruginosa populations (Cornforth
and Foster, 2013). However, this needs to be confirmed in
future experiments. Interestingly, all the clinical strains we used
originated from a single CF patient and interactions between
them thus reflect the realistic ecology of CF lungs. In the future,
it would be useful to determine pairwise interactions between
these CF strains and look at CORM effects on other coexisting
bacterial species observed in CF infections (Folkesson et al.,
2012).
We found that EBOR-CORM-1 had no clear therapeutic
benefits in the wax moth infection model. There are several
potential explanations for this. First, EBOR-CORM-1 had limited
long-term activity when in contact with water. As a result, the
bactericidal effect may only have elicited lag in the initial phase
of bacterial growth and proliferation within the wax moths.
Second, insect tissue is not homogeneous and it is possible that
we failed to deliver the CORM to the specific area of infection,
or that bacteria were able to colonize new areas that were not
exposed to the CORM. Third, insects differ from laboratory
media (such as LB) as a bacterial growth environment, which
could also affect pathogen virulence. For example, it has been
recently demonstrated that plant vs. animal based growth media
can have physiological effects on bacterial virulence (Ketola et al.,
2016) and that LBmedia does not adequately reflect P. aeruginosa
growth on lung tissue (Harrison et al., 2014; Harrison and
Diggle, 2016). Hence, the wax moth injection model might
not reliably reflect the virulence of CF isolates derived from
chronic infections. However, it is also the case that many of
the affordable and available CF infection animal models do not
truly reflect the real CF lung disease environment. It remains to
be established whether CORM therapy could be applied in the
context of CF lung infections. It is possible, for example, that
it might be more suitable for treating topical infections such
as burn wounds, for which better animal models are available
(Rumbaugh et al., 2012).
Further work is also needed to understand the mode of action
of EBOR-CORM-1. While respiratory oxidases and globins at
heme targets are generally considered the prime targets of CO
and CORMs (Wareham et al., 2015), it has been demonstrated
that CORMs can have multiple different other targets (Wilson
et al., 2015). For example, CO also binds to the di-iron site
in bacterial NO reductases and to iron, copper, and nickel
sites in certain microbial proteins such as CO dehydrogenase
(Lu et al., 2004; Wasser et al., 2005). In some cases, CORMs
might have intracellular targets but their accumulation within the
cells can be very weak (Tinajero-Trejo et al., 2016). Moreover,
in the future it would be important to test if EBOR-CORM-
1 is cytotoxic to eukaryotic cells. The concentration we used
are in line with previously published work where no, or very
mild, cytotoxic effects were observed (Murray et al., 2012).
We are currently conducting experiments to validate this
independently and to understand how EBOR-CORM-1 interacts
with bacterial cells. While, our wax moth assays show that the
concentrations we used had no negative effects on short-term
insect viability, more detailed cytotoxicity assays are needed
in the future. Lastly, the low solubility of EBOR-CORM-1
in water, and its activation in this medium, is problematic
for delivery and activation at specific sites within patients. In
addition to chemically increasing the molecule stability, CORMs
could be enclosed in microvesicles (van Dommelen et al.,
2012) to ensure more efficient antimicrobial activity and drug
delivery.
In conclusion, our results show that EBOR-CORM-1 shows
antimicrobial activity against both planktonic and biofilm cells
of P. aeruginosa strain PAO1 but that these effects are more
varied and less pronounced against clinical CF lung isolates in
monocultures. In contrast, more heterogeneous P. aeruginosa
populations comprising intraspecific phenotypic variants were
more susceptible to CORM treatment. This potentially has
wider implications in the testing of novel therapeutics. At
present, this is done almost exclusively using clonal P. aeruginosa
populations. Our observations suggest that testing carried out on
more heterogeneous populations of P. aeruginosa, more closely
resembling those found in the CF lung, may give different and
sometimes more promising results.
Frontiers in Microbiology | www.frontiersin.org 9 February 2018 | Volume 9 | Article 195
Flanagan et al. CORM Activity on Pseudomonas aeruginosa
AUTHOR CONTRIBUTIONS
LF, RS, KS, MK, BA, CW, IF, JL, AP, and V-PF designed and
performed the experiments. LF and V-PF analyzed the data and
all authors wrote the manuscript.
ACKNOWLEDGMENTS
We thank James Pitts for carrying out an initial EBOR-CORM-1
synthesis and TARGeTED Antimicrobial Resistance (AMR)
Project and EPSRC council for funding (EP/M027538/1). V-PF
is also supported by the Wellcome Trust (reference no. 105624)
through the Centre for Chronic Diseases and Disorders (C2D2)
at the University of York.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fmicb.
2018.00195/full#supplementary-material
REFERENCES
Angelici, R. J. (1964). Preparation, characterization, and reactions of the
cis-Dihalotetracarbonylmanganate (I) anions. Inorg. Chem. 3, 1099–1102.
doi: 10.1021/ic50018a008
Brown, E. D., and Wright, G. D. (2016). Antibacterial drug discovery in the
resistance era. Nature 529, 336–343. doi: 10.1038/nature17042
Cochran, W., Mcfeters, G., and Stewart, P. (2000). Reduced susceptibility of thin
Pseudomonas aeruginosa biofilms to hydrogen peroxide and monochloramine.
J. Appl. Microbiol. 88, 22–30. doi: 10.1046/j.1365-2672.2000.00825.x
Cornforth, D. M., and Foster, K. R. (2013). Competition sensing: the
social side of bacterial stress responses. Nat. Rev. Microbiol. 11, 285–293.
doi: 10.1038/nrmicro2977
de Beer, D., Stoodley, P., and Lewandowski, Z. (1997). Measurement of
local diffusion coefficients in biofilms by microinjection and confocal
microscopy. Biotechnol. Bioeng. 53, 151–158. doi: 10.1002/(SICI)1097-
0290(19970120)53:2<151::AID-BIT4>3.0.CO;2-N
de Beer, D., Stoodley, P., Roe, F., and Lewandowski, Z. (1994). Effects of biofilm
structures on oxygen distribution and mass transport. Biotechnol. Bioeng. 43,
1131–1138. doi: 10.1002/bit.260431118
Desmard, M., Davidge, K. S., Bouvet, O., Morin, D., Roux, D., Foresti, R., et al.
(2009). A carbon monoxide-releasing molecule (CORM-3) exerts bactericidal
activity against Pseudomonas aeruginosa and improves survival in an animal
model of bacteraemia. FASEB J. 23, 1023–1031. doi: 10.1096/fj.08-122804
El-Sayed, M., and Kaesz, H. (1963). Infrared spectra and structure of the
tetracarbonyl halide dimers of manganese, technetium, and rhenium. Inorg.
Chem. 2, 158–162. doi: 10.1021/ic50005a041
Flume, P. A., Mogayzel, P. J., Robinson, K. A., Rosenblatt, R. L., Quittell, L., and
Marshall, B. C. (2010). Cystic fibrosis pulmonary guidelines. Am. J. Respir. Crit.
Care Med. 182, 298–306. doi: 10.1164/rccm.201002-0157OC
Folkesson, A., Jelsbak, L., Yang, L., Johansen, H. K., Ciofu, O., Hoiby, N.,
et al. (2012). Adaptation of Pseudomonas aeruginosa to the cystic fibrosis
airway: an evolutionary perspective. Nat. Rev. Microbiol. 10, 841–851.
doi: 10.1038/nrmicro2907
Ghoul, M., West, S. A., Johansen, H. K., Molin, S., Harrison, O. B., Maiden,
M. C., et al. (2015). Bacteriocin-mediated competition in cystic fibrosis lung
infections. Proc. Biol. Sci. 282:20150972. doi: 10.1098/rspb.2015.0972
Harrison, F., and Diggle, S. P. (2016). An ex vivo lung model to study bronchioles
infected with Pseudomonas aeruginosa biofilms. Microbiology 162, 1755–1760.
doi: 10.1099/mic.0.000352
Harrison, F., Muruli, A., Higgins, S., and Diggle, S. P. (2014). Development
of an ex vivo porcine lung model for studying growth, virulence,
and signaling of Pseudomonas aeruginosa. Infect. Immun. 82, 3312–3323.
doi: 10.1128/IAI.01554-14
Harrison, F., Paul, J., Massey, R. C., and Buckling, A. (2008). Interspecific
competition and siderophore-mediated cooperation in Pseudomonas
aeruginosa. ISME J. 2, 49–55. doi: 10.1038/ismej.2007.96
Jimenez, J., Chakraborty, I., Carrington, S. J., and Mascharak, P. K. (2016).
Light-triggered CO delivery by a water-soluble and biocompatible manganese
photoCORM. Dalton Trans. 45, 13204–13213. doi: 10.1039/C6DT01358A
Ketola, T., Mikonranta, L., Laakso, J., and Mappes, J. (2016). Different food
sources elicit fast changes to bacterial virulence. Biol. Lett. 12:20150660.
doi: 10.1098/rsbl.2015.0660
Klein, M., Neugebauer, U., Gheisari, A., Malassa, A., Jazzazi, T. M., Froehlich, F.,
et al. (2014). IR spectroscopic methods for the investigation of the CO release
from CORMs. J. Phys. Chem. A 118, 5381–5390. doi: 10.1021/jp503407u
Lu, S., De Vries, S., and Moënne-Loccoz, P. (2004). Two CO molecules can bind
concomitantly at the Diiron Site of no reductase from Bacillus a zotoformans.
J. Am. Chem. Soc. 126, 15332–15333. doi: 10.1021/ja045233v
Marvig, R. L., Johansen, H. K., Molin, S., and Jelsbak, L. (2013). Genome analysis
of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive
mutations and distinct evolutionary paths of hypermutators. PLoS Genet.
9:e1003741. doi: 10.1371/journal.pgen.1003741
Motterlini, R., and Otterbein, L. E. (2010). The therapeutic potential of carbon
monoxide. Nat. Rev. Drug Discov. 9, 728–743. doi: 10.1038/nrd3228
Mowat, E., Paterson, S., Fothergill, J. L., Wright, E. A., Ledson, M. J., Walshaw, M.
J., et al. (2011). Pseudomonas aeruginosa population diversity and turnover in
cystic fibrosis chronic infections.Am. J. Respir. Crit. Care Med. 183, 1674–1679.
doi: 10.1164/rccm.201009-1430OC
Murray, T. S., Okegbe, C., Gao, Y., Kazmierczak, B. I., Motterlini, R., Dietrich,
L. E., et al. (2012). The carbon monoxide releasing molecule CORM-2
attenuates Pseudomonas aeruginosa biofilm formation. PLoS ONE 7:e35499.
doi: 10.1371/journal.pone.0035499
Nobre, L. S., Seixas, J. D., Romao, C. C., and Saraiva, L. M. (2007).
Antimicrobial action of carbon monoxide-releasing compounds. Antimicrob.
Agents Chemother. 51, 4303–4307. doi: 10.1128/AAC.00802-07
Normark, B. H., and Normark, S. (2002). Evolution and spread of antibiotic
resistance. J. Intern. Med. 252, 91–106. doi: 10.1046/j.1365-2796.2002.01026.x
O’Brien, S., Williams, D., Fothergill, J. L., Paterson, S., Winstanley, C., and
Brockhurst, M. A. (2017). High virulence sub-populations in Pseudomonas
aeruginosa long-term cystic fibrosis airway infections. BMC Microbiol. 17:30.
doi: 10.1186/s12866-017-0941-6
O’Neill, J. (2014). “Antimicrobial Resistance: Tackling a Crisis for the Health
and Wealth of Nations,” in Review on Antimicrobial Resistance (London: HM
Government &Wellcome Trust), 1–16.
Poole, K. (2011). Pseudomonas aeruginosa: resistance to the max. Front. Microbiol.
2:65. doi: 10.3389/fmicb.2011.00065
Pritt, B., O’brien, L., andWinn, W. (2007). Mucoid Pseudomonas in cystic fibrosis.
Am. J. Clin. Pathol. 128, 32–34. doi: 10.1309/KJRPC7DD5TR9NTDM
Reszka, K. J., O’malley, Y., Mccormick, M. L., Denning, G. M., and Britigan, B.
E. (2004). Oxidation of pyocyanin, a cytotoxic product from Pseudomonas
aeruginosa, by microperoxidase 11 and hydrogen peroxide. Free Radic. Biol.
Med. 36, 1448–1459. doi: 10.1016/j.freeradbiomed.2004.03.011
Rumbaugh, K. P., Trivedi, U.,Watters, C., Burton-Chellew,M.N., Diggle, S. P., and
West, S. A. (2012). Kin selection, quorum sensing and virulence in pathogenic
bacteria. Proc. Biol. Sci. 279, 3584–3588. doi: 10.1098/rspb.2012.0843
Smith, E. E., Buckley, D. G., Wu, Z., Saenphimmachak, C., Hoffman, L. R.,
D’argenio, D. A., et al. (2006). Genetic adaptation by Pseudomonas aeruginosa
to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. U.S.A. 103,
8487–8492. doi: 10.1073/pnas.0602138103
Stamellou, E., Storz, D., Botov, S., Ntasis, E., Wedel, J., Sollazzo, S., et al. (2014).
Different design of enzyme-triggered CO-releasing molecules (ET-CORMs)
reveals quantitative differences in biological activities in terms of toxicity and
inflammation. Redox Biol. 2, 739–748. doi: 10.1016/j.redox.2014.06.002
Stewart, P. S., and William Costerton, J. (2001). Antibiotic resistance of bacteria in
biofilms. Lancet 358, 135–138. doi: 10.1016/S0140-6736(01)05321-1
Frontiers in Microbiology | www.frontiersin.org 10 February 2018 | Volume 9 | Article 195
Flanagan et al. CORM Activity on Pseudomonas aeruginosa
Tinajero-Trejo, M., Rana, N., Nagel, C., Jesse, H. E., Smith, T. W., Wareham, L. K.,
et al. (2016). Antimicrobial activity of the manganese photoactivated carbon
monoxide-releasing molecule [Mn (CO) 3 (tpa-κ3N)]+ against a Pathogenic
Escherichia coli that causes urinary infections. Antioxid. Redox Signal. 24,
765–780. doi: 10.1089/ars.2015.6484
van Dommelen, S. M., Vader, P., Lakhal, S., Kooijmans, S., Van Solinge, W. W.,
Wood, M. J., et al. (2012). Microvesicles and exosomes: opportunities for cell-
derived membrane vesicles in drug delivery. J. Control. Release 161, 635–644.
doi: 10.1016/j.jconrel.2011.11.021
Ward, J. S., Lynam, J. M., Moir, J., and Fairlamb, I. J. (2014). Visible-light-
induced CO Release from a therapeutically viable tryptophan-derived
manganese (I) Carbonyl (TryptoCORM) exhibiting potent inhibition
against E. coli. Chem. A Eur. J. 20, 15061–15068. doi: 10.1002/chem.2014
03305
Ward, J. S., Morgan, R., Lynam, J. M., Fairlamb, I. J., and Moir, J. W.
(2017). Toxicity of tryptophan manganese (I) carbonyl (Trypto-CORM),
against Neisseria gonorrhoeae.Medchemcomm 8, 346–352. doi: 10.1039/C6MD
00603E
Wareham, L. K., Poole, R. K., and Tinajero-Trejo, M. (2015). CO-releasing metal
carbonyl compounds as antimicrobial agents in the post-antibiotic era. J. Biol.
Chem. 290, 18999–19007. doi: 10.1074/jbc.R115.642926
Wasser, I. M., Huang, H.-W., Moënne-Loccoz, P., and Karlin, K. D. (2005).
Heme/non-heme diiron (II) complexes and O2, CO, and NO adducts as
reduced and substrate-bound models for the active site of bacterial nitric
oxide reductase. J. Am. Chem. Soc. 127, 3310–3320. doi: 10.1021/ja04
58773
Who.Int (2010). WHO|Genes and Human Disease [Online]. Available online
at: http://www.who.int/genomics/public/geneticdiseases/en/index2.html
(Accessed Feb 16, 2017).
Williams, D., Evans, B., Haldenby, S., Walshaw, M. J., Brockhurst, M. A.,
Winstanley, C., et al. (2015). Divergent, coexisting Pseudomonas aeruginosa
lineages in chronic cystic fibrosis lung infections. Am. J. Respir. Crit. Care Med.
191, 775–785. doi: 10.1164/rccm.201409-1646OC
Williams, D., Paterson, S., Brockhurst, M. A., and Winstanley, C. (2016). Refined
analyses suggest that recombination is a minor source of genomic diversity
in Pseudomonas aeruginosa chronic cystic fibrosis infections. Microb. Genom.
2:e000051. doi: 10.1099/mgen.0.000051
Wilson, J. L., Wareham, L. K., Mclean, S., Begg, R., Greaves, S., Mann, B.
E., et al. (2015). CO-releasing molecules have nonheme targets in bacteria:
transcriptomic, mathematical modeling and biochemical analyses of CORM-3
[Ru(CO)3Cl(glycinate)] actions on a heme-deficient mutant of Escherichia coli.
Antioxid. Redox Signal. 23, 148–162. doi: 10.1089/ars.2014.6151
Winstanley, C., Langille, M. G., Fothergill, J. L., Kukavica-Ibrulj, I., Paradis-
Bleau, C., Sanschagrin, F., et al. (2009). Newly introduced genomic prophage
islands are critical determinants of in vivo competitiveness in the liverpool
epidemic strain of Pseudomonas aeruginosa. Genome Res. 19, 12–23.
doi: 10.1101/gr.086082.108
Winstanley, C., O’brien, S., and Brockhurst, M. A. (2016). Pseudomonas aeruginosa
evolutionary adaptation and diversification in cystic fibrosis chronic lung
infections. Trends Microbiol. 24, 327–337. doi: 10.1016/j.tim.2016.01.008
Workentine, M. L., Sibley, C. D., Glezerson, B., Purighalla, S., Norgaard-Gron,
J. C., Parkins, M. D., et al. (2013). Phenotypic heterogeneity of Pseudomonas
aeruginosa populations in a cystic fibrosis patient. PLoS ONE 8:e60225.
doi: 10.1371/journal.pone.0060225
Zhang, W.-Q., Atkin, A. J., Thatcher, R. J., Whitwood, A. C., Fairlamb, I. J., and
Lynam, J. M. (2009). Diversity and design of metal-based carbon monoxide-
releasing molecules (CO-RMs) in aqueous systems: revealing the essential
trends. Dalton Trans. 4351–4358. doi: 10.1039/b822157j
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Flanagan, Steen, Saxby, Klatter, Aucott, Winstanley, Fairlamb,
Lynam, Parkin and Friman. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and the
copyright owner are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction
is permitted which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 11 February 2018 | Volume 9 | Article 195
